Loading
A phase 2 trial in colorectal cancer, run by Centre hospitalier de l'Université de Montréal (CHUM), not yet recruiting.
Adaptive Radiotherapy for Safe Hypofractionation is a phase 2, randomised interventional study registered as NCT07516210 by Centre hospitalier de l'Université de Montréal (CHUM), with a registry enrolment figure of 264 participants, started 2026-05 and due to reach its primary completion in 2030-05. Interventions recorded: Adaptive Hypofractionated Radiotherapy; Standard-of-care Radiotherapy. Conditions listed: Cancer; Endometrial Cancer; Prostate Cancer; Cervical Cancer; Rectal Cancers. Primary outcome: Physician-reported Grade 2+ toxicity. Sites: Canada. No results are recorded here; the registry entry is the source.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.